CAR T cell therapy for solid tumors
K Newick, S O'Brien, E Moon… - Annual review of …, 2017 - annualreviews.org
The field of cancer immunotherapy has been re-energized by the application of chimeric
antigen receptor (CAR) T cell therapy in cancers. These CAR T cells are engineered to …
antigen receptor (CAR) T cell therapy in cancers. These CAR T cells are engineered to …
Chimeric antigen receptor T-cell therapy for solid tumors
K Newick, E Moon, SM Albelda - Molecular therapy-oncolytics, 2016 - cell.com
Chimeric antigen receptor (CAR) T cells are engineered constructs composed of synthetic
receptors that direct T cells to surface antigens for subsequent elimination. Many CAR …
receptors that direct T cells to surface antigens for subsequent elimination. Many CAR …
Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions
SJ Bagley, DM O'Rourke - Pharmacology & therapeutics, 2020 - Elsevier
Chimeric antigen receptor (CAR) T cells are a form of autologous immunotherapy that has
changed the therapeutic landscape of hematologic malignancies. CAR T cell therapy …
changed the therapeutic landscape of hematologic malignancies. CAR T cell therapy …
[HTML][HTML] CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment
M Martinez, EK Moon - Frontiers in immunology, 2019 - frontiersin.org
Chimeric antigen receptor (CAR) T cells, T cells that have been genetically engineered to
express a receptor that recognizes a specific antigen, have given rise to breakthroughs in …
express a receptor that recognizes a specific antigen, have given rise to breakthroughs in …
CAR T cell therapy for solid tumors: bright future or dark reality?
J Wagner, E Wickman, C DeRenzo, S Gottschalk - Molecular therapy, 2020 - cell.com
Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …
its success for hematological malignancies in clinical studies leading to the US Food and …
CAR-T cell therapy: current limitations and potential strategies
RC Sterner, RM Sterner - Blood cancer journal, 2021 - nature.com
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
CAR T cell therapy: a game changer in cancer treatment
H Almåsbak, T Aarvak… - Journal of immunology …, 2016 - Wiley Online Library
The development of novel targeted therapies with acceptable safety profiles is critical to
successful cancer outcomes with better survival rates. Immunotherapy offers promising …
successful cancer outcomes with better survival rates. Immunotherapy offers promising …
CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success
KB Long, RM Young, AC Boesteanu… - Frontiers in …, 2018 - frontiersin.org
Chimeric antigen receptor (CAR)-engineered T cells represent a breakthrough in
personalized medicine. In this strategy, a patient's own T lymphocytes are genetically …
personalized medicine. In this strategy, a patient's own T lymphocytes are genetically …
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps
GL Beatty, M O'Hara - Pharmacology & therapeutics, 2016 - Elsevier
Chimeric antigen receptor (CAR) T cell therapy has shown promise in CD19 expressing
hematologic malignancies, but how to translate this success to solid malignancies remains …
hematologic malignancies, but how to translate this success to solid malignancies remains …
[HTML][HTML] CAR T cells in solid tumors: blueprints for building effective therapies
HM Knochelmann, AS Smith, CJ Dwyer… - Frontiers in …, 2018 - frontiersin.org
Genetic redirection of T lymphocytes with chimeric antigen receptors (CARs) has soared
from treating cancers preclinically to FDA approval for hematologic malignancies and …
from treating cancers preclinically to FDA approval for hematologic malignancies and …